Press releases

Represents a first-of-its-kind treatment option in Canada for carotid artery disease

Companies intend to continue a pre-existing collaboration in the development of less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation.

Analyst meeting on Monday, February 23 will focus on the Company's outlook for 2004 and beyond.

New 120,000 square-foot building at the Maple Grove campus will house primarily research and development laboratories and offices.

Site will initially serve as the new headquarters for the Company's growing Endosurgery group.